Artículos de revistas sobre el tema "JAK/STAT inhibitors"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "JAK/STAT inhibitors".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Jones, Dan, Justin Windham, Brian Stewart, Luis Fayad, Alma Rodriguez y Fredrick B. Hagemeister. "Differential JAK-STAT Pathway Activation in Primary Mediastinal Large B-Cell Lymphoma: Two Subgroups with Differential Cytokine Activation Patterns and Predicted Responses to Kinase Inhibitors." Blood 114, n.º 22 (20 de noviembre de 2009): 968. http://dx.doi.org/10.1182/blood.v114.22.968.968.
Malemud, Charles J. "The role of the JAK/STAT signal pathway in rheumatoid arthritis". Therapeutic Advances in Musculoskeletal Disease 10, n.º 5-6 (19 de mayo de 2018): 117–27. http://dx.doi.org/10.1177/1759720x18776224.
Cacciapaglia, F., V. Venerito, S. del Vescovo, S. Stano, R. Bizzoca, D. Natuzzi, N. Lacarpia, M. Fornaro y F. Iannone. "AB0070 INHIBITION OF STAT3 IN PBMCs FROM RHEUMATOID ARTHRITIS PATIENTS: CLUES TO UNDERSTAND SELECTIVITY OF JANUS KINASE INHIBITORS". Annals of the Rheumatic Diseases 81, Suppl 1 (23 de mayo de 2022): 1167.2–1168. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1997.
Cacciapaglia, F., S. Perniola, S. del Vescovo, S. Stano, R. Bizzoca, D. Natuzzi, M. Fornaro y F. Iannone. "AB0134 IN-VITRO STUDY ON THE EFFECT OF SELECTIVE Jak-INHIBITORS ON PBMCs STAT3 PHOSPHORYLATION FROM SYSTEMIC SCLEROSIS PATIENTS". Annals of the Rheumatic Diseases 81, Suppl 1 (23 de mayo de 2022): 1196.3–1197. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2625.
Conzelmann, Michael, Elena Rodionova, Michael Hess, Thomas Giese, Anthony D. Ho, Peter Dreger y Thomas Luft. "Complementary JAK/STAT Signalling Is Required for the Pro-Inflammatory Effects of CD40 Ligation: Differential Effects in Human Myeloid and B Cells." Blood 110, n.º 11 (16 de noviembre de 2007): 2413. http://dx.doi.org/10.1182/blood.v110.11.2413.2413.
Galli Sanchez, Ana Paula, Tatiane Ester Aidar Fernandes y Gustavo Martelli Palomino. "The JAK-STAT Pathway and the JAK Inhibitors". Journal of Clinical Research in Dermatology 7, n.º 5 (30 de noviembre de 2020): 1–6. http://dx.doi.org/10.15226/2378-1726/7/5/001128.
Raivola, Juuli, Teemu Haikarainen, Bobin George Abraham y Olli Silvennoinen. "Janus Kinases in Leukemia". Cancers 13, n.º 4 (14 de febrero de 2021): 800. http://dx.doi.org/10.3390/cancers13040800.
Raivola, Juuli, Teemu Haikarainen y Olli Silvennoinen. "Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling". Cancers 12, n.º 1 (27 de diciembre de 2019): 78. http://dx.doi.org/10.3390/cancers12010078.
Bhagwat, Neha, Priya Koppikar, Outi Kilpivaara, Taghi Manshouri, Mazhar Adli, Ann Mullally, Omar Abdel-Wahab et al. "Heterodimeric JAK-STAT Activation As a Mechanism of Persistence to JAK2 Inhibitor Therapy". Blood 118, n.º 21 (18 de noviembre de 2011): 122. http://dx.doi.org/10.1182/blood.v118.21.122.122.
Meyer, Sara C., Matthew D. Keller, Priya Koppikar, Olga A. Guryanova, Maria Kleppe, Anna Sophia McKenney, William R. Sellers et al. "Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models". Blood 124, n.º 21 (6 de diciembre de 2014): 160. http://dx.doi.org/10.1182/blood.v124.21.160.160.
Gorre, M., I. Jilani, H. Kantarjian, F. Giles, A. Hannah y M. Albitar. "Novel Quantitative Flow Cytometry-Based Signaling Assays Reveal a Potential Role for HSP90 Inhibitors in the Treatment of JAK2 Mutant-Positive Diseases." Blood 106, n.º 11 (16 de noviembre de 2005): 3526. http://dx.doi.org/10.1182/blood.v106.11.3526.3526.
Callus, Bernard A. y Bernard Mathey-Prevot. "Interleukin-3–Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors". Blood 91, n.º 9 (1 de mayo de 1998): 3182–92. http://dx.doi.org/10.1182/blood.v91.9.3182.
Callus, Bernard A. y Bernard Mathey-Prevot. "Interleukin-3–Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors". Blood 91, n.º 9 (1 de mayo de 1998): 3182–92. http://dx.doi.org/10.1182/blood.v91.9.3182.3182_3182_3192.
Hashemi, David y Neal Bhatia. "The JAK-Cytokine Interface – A Review and Update on Prospective Clinical Considerations". SKIN The Journal of Cutaneous Medicine 7, n.º 4 (17 de julio de 2023): 932–35. http://dx.doi.org/10.25251/skin.7.4.16.
Shawky, Ahmed M., Faisal A. Almalki, Ashraf N. Abdalla, Ahmed H. Abdelazeem y Ahmed M. Gouda. "A Comprehensive Overview of Globally Approved JAK Inhibitors". Pharmaceutics 14, n.º 5 (6 de mayo de 2022): 1001. http://dx.doi.org/10.3390/pharmaceutics14051001.
Musumeci, Francesca, Chiara Greco, Ilaria Giacchello, Anna Lucia Fallacara, Munjed M. Ibrahim, Giancarlo Grossi, Chiara Brullo y Silvia Schenone. "An Update on JAK Inhibitors". Current Medicinal Chemistry 26, n.º 10 (20 de junio de 2019): 1806–32. http://dx.doi.org/10.2174/0929867325666180327093502.
Suzuki, Asuka, Toshikatsu Hanada, Keiichi Mitsuyama, Takafumi Yoshida, Shintaro Kamizono, Tomoaki Hoshino, Masato Kubo et al. "Cis3/Socs3/Ssi3 Plays a Negative Regulatory Role in Stat3 Activation and Intestinal Inflammation". Journal of Experimental Medicine 193, n.º 4 (12 de febrero de 2001): 471–82. http://dx.doi.org/10.1084/jem.193.4.471.
Thomas, Sally J., Katherine Fisher, Stephen Brown, John A. Snowden, Sarah Danson y Martin Zeidler. "Methotrexate Is a Suppressor of JAK/STAT Pathway Activation Which Inhibits JAK2V617F Induced Signalling". Blood 124, n.º 21 (6 de diciembre de 2014): 4577. http://dx.doi.org/10.1182/blood.v124.21.4577.4577.
Taldaev, Amir, Vladimir R. Rudnev, Kirill S. Nikolsky, Liudmila I. Kulikova y Anna L. Kaysheva. "Molecular Modeling Insights into Upadacitinib Selectivity upon Binding to JAK Protein Family". Pharmaceuticals 15, n.º 1 (25 de diciembre de 2021): 30. http://dx.doi.org/10.3390/ph15010030.
Moser, Bernhard, Sophie Edtmayer, Agnieszka Witalisz-Siepracka y Dagmar Stoiber. "The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia". Biomedicines 9, n.º 8 (19 de agosto de 2021): 1051. http://dx.doi.org/10.3390/biomedicines9081051.
Zhang, Xuekang, Jun Zhou, Qian Hu, Zhengren Liu, Qiuhong Chen, Wenxiang Wang, Huaigen Zhang, Qin Zhang y Yuanlu Huang. "The Role of Janus Kinase/Signal Transducer and Activator of Transcription Signalling on Preventing Intestinal Ischemia/Reperfusion Injury with Dexmedetomidine". Journal of Nanoscience and Nanotechnology 20, n.º 5 (1 de mayo de 2020): 3295–302. http://dx.doi.org/10.1166/jnn.2020.16416.
Zheng, Ying, Hongwei Qin, Stuart J. Frank, Luqin Deng, David W. Litchfield, Ayalew Tefferi, Animesh Pardanani et al. "A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway". Blood 118, n.º 1 (7 de julio de 2011): 156–66. http://dx.doi.org/10.1182/blood-2010-01-266320.
Hu, Cheng-Ping, Jun-Tao Feng, Yu-Ling Tang, Jin-Qi Zhu, Min-Juan Lin y Ming-En Yu. "LIF Upregulates Expression of NK-1R in NHBE Cells". Mediators of Inflammation 2006 (2006): 1–8. http://dx.doi.org/10.1155/mi/2006/84829.
Kim, Jung Eun, Yu Jin Lee, Hye Ree Park, Dong Geon Lee, Kwan Ho Jeong y Hoon Kang. "The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells". International Journal of Molecular Sciences 21, n.º 14 (20 de julio de 2020): 5137. http://dx.doi.org/10.3390/ijms21145137.
Karati, Dipanjan, Kakasaheb Ramoo Mahadik, Piyush Trivedi y Dileep Kumar. "The Emerging Role of Janus Kinase Inhibitors in the Treatment of Cancer". Current Cancer Drug Targets 22, n.º 3 (marzo de 2022): 221–33. http://dx.doi.org/10.2174/1568009622666220301105214.
Kapuria, Vaibhav, Geoffrey Bartholomeusz, Ling-Yuan Kong, William Bornmann, Zhenghong Peng, Ashutosh Pal, David Maxwell, Moshe Talpaz y Nicholas Donato. "A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling." Blood 110, n.º 11 (16 de noviembre de 2007): 1556. http://dx.doi.org/10.1182/blood.v110.11.1556.1556.
Springuel, Lorraine, Tekla Hornakova, Elisabeth Losdyck, Fanny Lambert, Emilie Leroy, Stefan N. Constantinescu, Elisabetta Flex, Marco Tartaglia, Laurent Knoops y Jean-Christophe Renauld. "Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors". Blood 124, n.º 26 (18 de diciembre de 2014): 3924–31. http://dx.doi.org/10.1182/blood-2014-05-576652.
Sonkin, Dmitriy, Catherine Regnier, Xianhui Rong, Christie Fanton, Michael Palmer, Jocelyn Holash, Matthew Squires et al. "Identification of pSTAT5 gene signature in hematologic malignancy." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): 7111. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.7111.
Haysen, S., A. L. L. Nielsen, P. Qvist y T. W. Kragstrup. "POS0038 GENOMICS OF JAK-STAT SIGNALING IN VENOUS THROMBOEMBOLISM". Annals of the Rheumatic Diseases 81, Suppl 1 (23 de mayo de 2022): 234.1–234. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2593.
Jeong, Ga Hee y Ji Hyun Lee. "Dysregulated Hippo Signaling Pathway and YAP Activation in Atopic Dermatitis: Insights from Clinical and Animal Studies". International Journal of Molecular Sciences 24, n.º 24 (10 de diciembre de 2023): 17322. http://dx.doi.org/10.3390/ijms242417322.
Perner, Florian, Felix C. Saalfeld, Tina M. Schnoeder, Denise Wolleschak, Corinna Fahldieck, Satish Ranjan, Berend H. Isermann et al. "Specificity of JAK-Kinase Inhibition Determines Impact on T-Cell Function". Blood 124, n.º 21 (6 de diciembre de 2014): 1410. http://dx.doi.org/10.1182/blood.v124.21.1410.1410.
Purandare, Ashok V., Animesh Pardanani, Theresa McDevitt, Marco Gottardis, Terra Lasho, Dan You, Louis Lombardo et al. "Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2". Blood 116, n.º 21 (19 de noviembre de 2010): 4112. http://dx.doi.org/10.1182/blood.v116.21.4112.4112.
Lim, Ken-Hong, Yu-Cheng Chang, Yi-Hao Chiang, Huan-Chau Lin, Ling Huang, Wei-Ting Wang, Ying-Wen Su, Ming-Chih Chang, Yi-Fang Chang y Caleb Gon-Shen Chen. "Acquired Resistance to JAK Inhibitors in Calr-Mutated Myeloproliferative Neoplasms". Blood 134, Supplement_1 (13 de noviembre de 2019): 2970. http://dx.doi.org/10.1182/blood-2019-124420.
Rodman, Esther, Michael Emch, Elizabeth Bruinsma, Xiaonan Hou, John Weroha y John Hawse. "Abstract 1129: Interrogating JAK/STAT signaling in ovarian cancer as a potential oncogenic driver and therapeutic target". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 1129. http://dx.doi.org/10.1158/1538-7445.am2022-1129.
Clarke, A., J. Di Paolo, B. Downie, A. Meng, N. Mollova, Y. Yu y P. Han. "P460 Evaluation of potential mechanisms underlying the safety observations of filgotinib in clinical studies in rheumatoid arthritis". Journal of Crohn's and Colitis 14, Supplement_1 (enero de 2020): S409. http://dx.doi.org/10.1093/ecco-jcc/jjz203.589.
Ross, David M., Jeffrey J. Babon, Denis Tvorogov y Daniel Thomas. "Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications". Haematologica 106, n.º 5 (21 de enero de 2021): 1244–53. http://dx.doi.org/10.3324/haematol.2020.262691.
Montero, Paula, Javier Milara, Inés Roger y Julio Cortijo. "Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms". International Journal of Molecular Sciences 22, n.º 12 (9 de junio de 2021): 6211. http://dx.doi.org/10.3390/ijms22126211.
Banes, Amy K., Séan Shaw, John Jenkins, Heather Redd, Farhad Amiri, David M. Pollock y Mario B. Marrero. "Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli". American Journal of Physiology-Renal Physiology 286, n.º 4 (abril de 2004): F653—F659. http://dx.doi.org/10.1152/ajprenal.00163.2003.
Jang, Sun Hee y Ji Hyeon Ju. "Janus kinase inhibitors for the treatment of rheumatoid arthritis". Journal of the Korean Medical Association 64, n.º 2 (10 de febrero de 2021): 105–8. http://dx.doi.org/10.5124/jkma.2021.64.2.105.
Simon, Amy R., Satoe Takahashi, Mariano Severgnini, Barry L. Fanburg y Brent H. Cochran. "Role of the JAK-STAT pathway in PDGF-stimulated proliferation of human airway smooth muscle cells". American Journal of Physiology-Lung Cellular and Molecular Physiology 282, n.º 6 (1 de junio de 2002): L1296—L1304. http://dx.doi.org/10.1152/ajplung.00315.2001.
Liu, Liqin, Violeta Yu, Jeanne Pistillo, Josie Lee, Laurie B. Schenkel, Stephanie Geuns-Meyer, Ivonne Archibeque, Angus Sinclair, Renee Emkey y Graham Molineux. "New Insights on Assessing Intra-Family Selectivity for Jak2 Inhibitors". Blood 118, n.º 21 (18 de noviembre de 2011): 5150. http://dx.doi.org/10.1182/blood.v118.21.5150.5150.
Pérez, Cristina, Julia Gonzalez-Rincon, Carmen Almaraz, Soraya Curiel, Nuria Garcia, Helena Pisonero, Sagrario Gomez et al. "A Role of JAK/STAT Pathway in Cutaneous T-Cell Lymphomas: Exploring Its Effects for Targeted Therapy". Blood 124, n.º 21 (6 de diciembre de 2014): 4498. http://dx.doi.org/10.1182/blood.v124.21.4498.4498.
Hindupur, Sruthi V., Sebastian C. Schmid, Jana Annika Koch, Ahmed Youssef, Eva-Maria Baur, Dongbiao Wang, Thomas Horn et al. "STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy". International Journal of Molecular Sciences 21, n.º 3 (7 de febrero de 2020): 1106. http://dx.doi.org/10.3390/ijms21031106.
Barton, Beverly E., James G. Karras, Thomas F. Murphy, Arnold Barton y Hosea F.-S. Huang. "Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines". Molecular Cancer Therapeutics 3, n.º 1 (1 de enero de 2004): 11–20. http://dx.doi.org/10.1158/1535-7163.11.3.1.
Westfall, Matt, Rachael E. Hawtin, Diane Longo, Michelle Cholankeril, Reena K. Vora, Michelle Atallah, Alessandra Cesano, Steven L. Allen y Scott Z. Fields. "Functional Pathway Analysis Of JAK2 Mutated and Wild Type Myeloproliferative Neoplasms As a Tool For Patient Stratification and Therapeutic Selection". Blood 122, n.º 21 (15 de noviembre de 2013): 5263. http://dx.doi.org/10.1182/blood.v122.21.5263.5263.
Fujita, M., K. Fukuda, S. Hayashi, K. Kikuchi, Y. Takashima, T. Kamenaga, T. Maeda, T. Matsubara y R. Kuroda. "AB0089 THE ANALYSIS FOR THE INHIBITION OF ANGIOGENESIS BY JAK INHIBITOR". Annals of the Rheumatic Diseases 79, Suppl 1 (junio de 2020): 1344.2–1344. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3161.
Severin, Frezzato, Visentin, Martini, Trimarco, Carraro, Tibaldi et al. "In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment". Cancers 11, n.º 12 (4 de diciembre de 2019): 1939. http://dx.doi.org/10.3390/cancers11121939.
Chen, Jing, Yong Zhang, Michael N. Petrus, Wenming Xiao, Alina Nicolae, Mark Raffeld, Stefania Pittaluga et al. "Cytokine receptor signaling is required for the survival of ALK− anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations". Proceedings of the National Academy of Sciences 114, n.º 15 (29 de marzo de 2017): 3975–80. http://dx.doi.org/10.1073/pnas.1700682114.
Vian, Laura, Mimi Lee, Giuseppe Sciumè, Nathalia Gazaniga, Stefania Dell'Orso, Stephen Brooks y Massimo Gadina. "Elucidating the role of cytokine signaling in the homeostasis of innate immune cells with JAK inhibitors". Journal of Immunology 202, n.º 1_Supplement (1 de mayo de 2019): 181.27. http://dx.doi.org/10.4049/jimmunol.202.supp.181.27.
Han, Yaguang, Yan Zhang, Ying Tian, Miao Zhang, Cheng Xiang, Qiang Zhen, Jiabao Liu et al. "The Interaction of the IFNγ/JAK/STAT1 and JAK/STAT3 Signalling Pathways in EGFR-Mutated Lung Adenocarcinoma Cells". Journal of Oncology 2022 (21 de septiembre de 2022): 1–16. http://dx.doi.org/10.1155/2022/9016296.